ALLOVIR
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
ALLOVIR
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2013-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.allovir.com
Total Employee:
101+
Status:
Active
Contact:
(346)772-0319
Total Funding:
360.59 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Tag Manager Google Maps Content Delivery Network LetsEncrypt Amazon ReCAPTCHA
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Advisor
2017-10-01
Board_member
2019-10-01
Current Employees Featured
Juan Vera Chief Product Development Officer @ AlloVir
Chief Product Development Officer
Ann Leen Co-Founder & Chief Scientific Officer @ AlloVir
Co-Founder & Chief Scientific Officer
2013-01-01
Diana Brainard Chief Executive Officer @ AlloVir
Chief Executive Officer
2021-05-01
Edward Miller General Counse & Secretary @ AlloVir
General Counse & Secretary
2018-09-01
Melissa Stundick Senior Vice President Business Development @ AlloVir
Senior Vice President Business Development
2022-03-01
Dana Alexander SVP Technical Operations @ AlloVir
SVP Technical Operations
2020-09-01
Vikas Sinha President & CFO @ AlloVir
President & CFO
2018-10-01
Founder
Stock Details
Investors List
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - AlloVir
Invus
Invus investment in Post-IPO Equity - AlloVir
Kite Pharma
Kite Pharma investment in Post-IPO Equity - AlloVir
GMT Capital
GMT Capital investment in Post-IPO Equity - AlloVir
Redmile Group
Redmile Group investment in Post-IPO Equity - AlloVir
ElevateBio
ElevateBio investment in Post-IPO Equity - AlloVir
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - AlloVir
F2 Ventures
F2 Ventures investment in Post-IPO Equity - AlloVir
Fidelity
Fidelity investment in Series B - AlloVir
Leerink Partners
Leerink Partners investment in Series B - AlloVir
Key Employee Changes
| Date | New article |
|---|---|
| 2023-05-16 | AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer |
| 2021-12-16 | AlloVir Announces Departure of Chief Medical Officer Augustin Melian |
Official Site Inspections
http://www.allovir.com Semrush global rank: 6.25 M Semrush visits lastest month: 1.07 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "AlloVir"
AlloVir | Allogeneic Cell Therapies Fighting Viral Infections
Our allogeneic, virus-specific T cell (VST) therapy candidates target 11 different devastating viruses as treatment or prevention. Our proprietary platform develops off-the-shelf VSTs that …See details»
Investor Relations | AlloVir, Inc.
Nov 8, 2024 · The Investor Relations website contains information about AlloVir, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
AlloVir - LinkedIn
AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The …See details»
Our Story - AlloVir
AlloVir is committed to preventing and defeating life-threatening viral diseases by delivering revolutionary, allogeneic cell therapies to patients fighting viral infections.See details»
AlloVir - Crunchbase Company Profile & Funding
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from …See details»
AlloVir, Inc. - AnnualReports.com
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.See details»
Our Platform - AlloVir
AlloVir is developing revolutionary, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients fighting viral infections.See details»
A Leader in Allogeneic, Off-the-Shelf, Virus- Specific ... - AlloVir, Inc.
This presentation has been prepared by AlloVir, Inc. (“we,” “us,” “our,” “AlloVir” or the “Company”) and is made for informational purposes only. This presentation may contain “forward-looking …See details»
Company Profile for AlloVir - Business Wire
Dec 10, 2020 · AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell …See details»
Company Profile for AlloVir - Nasdaq
Dec 10, 2020 · AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell …See details»
AlloVir Company Profile - Office Locations, Competitors ... - Craft
Sep 6, 2024 · AlloVir (formerly known as ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases.See details»
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel …
Mar 22, 2022 · AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients …See details»
AlloVir (Nasdaq:ALVR) - Stock Price, News & Analysis - Simply Wall …
2 days ago · Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent …See details»
AlloVir (ALVR) Earnings Date and Reports 2024 - MarketBeat
2 days ago · AlloVir announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.04, which beat analysts' consensus estimates of -$0.14 by $0.10. AlloVir currently has a …See details»
AlloVir, Inc. enters definitive merger agreement to combine with ...
Nov 18, 2024 · Diana Brainard, CEO of AlloVir, also shared her thoughts on the benefits of this merger in the press release 1, saying, “AlloVir ran a thorough and strategic process, and we …See details»
AlloVir shedding 95% of its staff after discontinuing T cell therapy ...
Jan 4, 2024 · AlloVir Inc. (ALVR), a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an …See details»
Pipeline - AlloVir
We are advancing a pipeline of allogeneic, off-the-shelf virus-specific T cell (VST) therapies to treat or prevent life-threatening viral diseases with limited to no treatment options in …See details»
Struggling AlloVir finds new identity via disease biotech merger
Nov 8, 2024 · AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. Now, the immunotherapy biotech has found a new path …See details»
ALVR109 | Therapy candidate for COVID-19 - AlloVir
Novel therapeutics, including ALVR109, an allogeneic, off-the-shelf, SARS-CoV-2-specific T cell (VST) therapy candidate for COVID-19, may be of benefit to address this urgent unmet …See details»
AlloVir and Kalaris Therapeutics to Merge | News & Events | Goodwin
Nov 8, 2024 · The Goodwin Life Sciences and Public M&A teams advised AlloVir (Nasdaq: ALVR) on its definitive merger agreement to combine with Kalaris Therapeutics, a clinical-stage …See details»